Continuous infusion of beta-lactam antibiotics

Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics

Volumn , Issue , 2014, Pages 223-255

  Muller, Anouk E ^a   Mouton, Johan W ^b  

^a Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Beta lactams; Continuous infusion; Dose calculation; Pharmacodynamic target; Prolonged or extended infusion

Indexed keywords

EID: 84926399012     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-75613-4_10     Document Type: Chapter

References (130)

1. Adembri C, Ristori R, Chelazzi C., Arrigucci S, Cassetta MI, De Gaudio AR et al (2010) Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters. J Thorac Cardiovasc Surg 140(2):471-475
2. Alou L, Aguilar L, Sevillano D., Gimenez MJ, Echeverria O, Gomez-Lus ML et al (2005) Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother 55(2):209-213
3. Ashwin J, Lynn B, Taskin C.B. (1987) Stability and administration of intravenous Augmentin. Pharm J 238:116-119
4. Baririan N, Chanteux H, Viaene E., Servais H, Tulkens P.M. (2003) Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 51(3):651-658
5. Bayard DS, Jelliffe R.W. (2004) A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn 31(1):75-107
6. Benko AS, Cappelletty DM, Kruse J.A., Rybak M.J. (1996) Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 40(3):691-695
7. Berkhout J, Visser LG, van den Broek PJ, van de Klundert JA, Mattie H (2003) Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion. Antimicrob Agents Chemother 47(6):1862-1866
8. Bernard L, El H, Pron B., Lotthe A, Gleizes V, Signoret F et al (2001) Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J Clin Pharm Ther 26(6):445-451
9. Bertels RA, Semmekrot BA, Gerrits G.P., Mouton J.W. (2008) Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusion. Infection 36(5):415-420
10. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens P.M. (2010) Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 65(5):1073-1075
11. Bodey GP, Ketchel SJ, Rodriguez V. (1979) A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 67(4): 608-616
12. Boselli E, Breilh D, Saux M.C., Gordien JB, Allaouchiche B. (2006) Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med 32(12):2059-2062
13. Bowker KE, Holt HA, Reeves D.S., MacGowan A.P. (1996) Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. J Antimicrob Chemother 38(6):1055-1060
14. Brink AJ, Richards GA, Schillack V, Kiem S., Schentag J. (2009) Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents 33(5):432-436
15. Buijk SL, Gyssens IC, Mouton J.W., Van Vliet A, Verbrugh HA, Bruining H.A. (2002) Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 49(1):121-128
16. Buijk SE, Gyssens IC, Mouton J.W., Metselaar HJ, Groenland TH, Verbrugh HA et al (2004a) Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J Antimicrob Chemother 54(1):199-205
17. Buijk SE, Gyssens IC, Mouton J.W., Metselaar HJ, Groenland TH, Verbrugh HA et al (2004b) Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J Antimicrob Chemother 54:194-205
18. Buijs J, Dofferhoff AS, Mouton J.W., van der Meer JW (2007) Continuous administration of PBP2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis. J Antimicrob Chemother 59(5):926-933
19. Burgess DS, Waldrep T. (2002) Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther 24(7): 1090-1104
20. Burgess DS, Summers KK, Hardin T.C. (1999) Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Clin Ther 21(11):1882-1889
21. Burgess DS, Hastings RW, Hardin T.C. (2000) Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 22(1):66-75
22. Burkhardt O, Kumar V, Katterwe D., Majcher-Peszynska J, Drewelow B, Derendorf H et al (2007) Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 59(2):277-284
23. Cappelletty DM, Kang SL, Palmer S.M., Rybak M.J. (1995) Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother 39(8):1797-1801
24. Claus B, Buyle F, Robays H., Vogelaers D. (2010) Importance of infusion volume and pump characteristics in extended administration of ss-lactam antibiotics. Antimicrob Agents Chemother 54(11):4950
25. Craig WA, Ebert S.C. (1992) Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36(12):2577-2583
26. Croisier D, Martha B, Piroth L., Chavanet P. (2008) In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia. Int J Antimicrob Agents 32(6):494-498
27. Daenen S, Erjavec Z, Uges D.R., De Vries-Hospers HG, De Jonge P, Halie MR (1995) Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 14(3):188-192
28. Dailly E, Kergueris MF, Pannier M, Jolliet P., Bourin M. (2003) Population pharmacokinetics of imipenem in burn patients. Fundam Clin Pharmacol 17(6):645-650
29. Dalle JH, Gnansounou M, Husson M.O., Lambilliotte A., Mazingue F, Nelken B. (2002) Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer. J Pediatr Hematol Oncol 24(9):714-716
30. De Jongh R., Hens R, Basma V., Mouton JW, Tulkens PM, Carryn S. (2008) Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 61(2):382-388
31. Donskey CJ (2004) The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 39(2):219-226
32. Drusano GL (1990) Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis Suppl 74:235-248
33. Dulhunty JM, Roberts JA, Davis J.S., Webb SA, Bellomo R, Gomersall C, Shirwadkar C., Eastwood GM, Myburgh J, Paterson DL, Lipman J. (2013) Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 56(2):236-244
34. Eagle H, Fleischman R, Musselman A.D. (1950) Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels. Am J Med 9(3):280-299
35. Eagle H, Fleischman R, Levy M. (1953a) On the duration of penicillin action in relation to its concentration in the serum. J Lab Clin Med 41(1):122-132
36. Eagle H, Fleischman R, Levy M. (1953b) "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med 248(12):481-488
37. Felton TW, Hope WW, Lomaestro B.M., Butterfield JM, Kwa AL, Drusano GL et al (2012) Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother 56(8):4087-4094
38. Florey K (1988) Aztreonam. In: Florey K (ed) Analytical profiles of drug substances. Academic, San Diego, pp 3-39
39. Friedrich LV, White RL, Kays M.B., Brundage DM, Yarbrough D III (1991) Aztreonam pharmacokinetics in burn patients. Antimicrob Agents Chemother 35(1):57-61
40. Garnacho-Montero J., Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C (2003) Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31(12): 2742-2751
41. Garnacho-Montero J., Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jimenez R., Barroso S et al (2006) Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 10(4):R111
42. Gault MH, Cockcroft D.W. (1975) Letter: creatinine clearance and age. Lancet 2 (7935):612-613
43. Georges B, Conil JM, Cougot P, Decun J.F., Archambaud M., Seguin T et al (2005) Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 43(8):360-369
44. Gilbert DN, Dworkin RJ, Raber S.R., Leggett J.E. (1997) Outpatient parenteral antimicrobial-drug therapy. N Engl J Med 337(12):829-838
45. Goessens WH, Mouton JW, Ten Kate MT, Bijl AJ, Ott A, Bakker-Woudenberg IA (2007) Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection. J Antimicrob Chemother 59(3):507-516
46. Grant EM, Kuti JL, Nicolau D.P., Nightingale C., Quintiliani R. (2002) Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 22(4):471-483
47. Hanes SD, Wood GC, Herring V, Croce M.A., Fabian TC, Pritchard E et al (2000) Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 179(6):436-440
48. Harbarth S, Garbino J, Pugin J., Romand JA, Lew D, Pittet D. (2003) Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 115(7):529-535
49. Howden BP, Richards M.J. (2001) The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis. J Antimicrob Chemother 48(2): 311-314
50. Hubert D, Le Roux E, Lavrut T, Wallaert B., Scheid P, Manach D et al (2009) Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 53(9):3650-3656
51. Hyatt JM, Nix DE, Stratton C.W., Schentag J.J. (1995) In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 39(8):1711-1716
52. Jawetz E (1946) Dynamics of the action of penicillin in experimental animals: observations in mice. Arch Intern Med 7:1-15
53. Keel RA, Sutherland CA, Crandon J.L., Nicolau D.P. (2011) Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents 37(2):184-185
54. Kollef MH, Sherman G, Ward S., Fraser V.J. (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115(2):462-474
55. Kuti JL, Nightingale CH, Knauft R.F., Nicolau D.P. (2004) Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 26(4):493-501
56. Lau WK, Mercer D, Itani K.M., Nicolau DP, Kuti JL, Mansfield D et al (2006) Randomized, openlabel, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 50(11):3556-3561
57. Leder K, Turnidge JD, Korman T.M., Grayson M.L. (1999) The clinical efficacy of continuousinfusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 43(1): 113-118
58. Leggett JE (2000) Ambulatory use of parenteral antibacterials: contemporary perspectives. Drugs 59(Suppl 3):1-8, discussion 47-9
59. Leggett JE, Fantin B, Ebert S., Totsuka K, Vogelman B, Calame W et al (1989) Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thighinfection models. J Infect Dis 159(2):281-292
60. Leggett JE, Ebert S, Fantin B., Craig W.A. (1990) Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl 74:179-184
61. Lipman J, Gomersall CD, Gin T, Joynt G.M., Young R.J. (1999) Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 43:309-311
62. Livingston DH, Wang M.T. (1993) Continuous infusion of cefazolin is superior to intermittent dosing in decreasing infection after hemorrhagic shock. Am J Surg 165(2):203-207
63. Lodise TP, Butterfield J. (2011) Use of pharmacodynamic principles to inform beta-lactam dosing: "S" does not always mean success. J Hosp Med 6(Suppl 1):S16-S23
64. Lodise TP J.r., Lomaestro B, Drusano G.L. (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44(3):357-363
65. Lorente L, Lorenzo L, Martin M.M., Jimenez A., Mora M.L. (2006) Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 40(2):219-223
66. Lorente L, Jimenez A, Martin M.M., Iribarren JL, Jimenez JJ, Mora M.L. (2009) Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 33(5):464-468
67. MacGowan A (2011) Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol 11(5):470-476
68. Mathot RAA, de Graaf AI, Vinks A.A. (1997) Stability of meropenem in a portable pump reservoir. Clin Microbiol Infect 88(Suppl 2):393
69. Mohd Hafiz A.A., Staatz CE, Kirkpatrick C.M., Lipman J., Roberts J.A. (2011) Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. Minerva Anestesiol 78(1):94-104
70. Mouton JW, den Hollander JG (1994) Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38(5):931-936
71. Mouton JW, Michel M.F. (1991) Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. J Antimicrob Chemother 28(6):911-918
72. Mouton JW, Vinks A.A. (1996) Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 38(1):5-15
73. Mouton JW, Vinks A.A. (2005a) PK-PD modelling of antibiotics in vitro and in vivo using bacterial growth and kill kinetics: the MIC vs stationary concentrations. Clin Pharmacokinet 44:201-210
74. Mouton JW, Vinks A.A. (2005b) Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 44(2):201-210
75. Mouton JW, Vinks A.A. (2007) Continuous infusion of beta-lactams. Curr Opin Crit Care 13(5):598-606
76. Mouton JW, Horrevorts AM, Mulder P.G., Prens EP, Michel M.F. (1990) Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 34(12):2307-2311
77. Muller AE, Punt N, Mouton J.W. (2013) Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 68(4):900-906
78. Naziri W, Cheadle WG, Trachtenberg L.S., Montgomery WD, Polk HC Jr (1995) Second place winner of the Conrad Jobst Award in the gold medal paper competition. Increased antibiotic effectiveness in a model of surgical infection through continuous infusion. Am Surg 61(1):11-15
79. Neftel KA, Walti M, Spengler H., de Weck AL (1982) Effect of storage of penicillin-G solutions on sensitisation to penicillin-G after intravenous administration. Lancet 1 (8279):986-988
80. Neftel KA, Walti M, Schulthess H.K., Gubler J. (1984) Adverse reactions following intravenous penicillin-G relate to degradation of the drug in vitro. Klin Wochenschr 62(1):25-29
81. Nicolau DP, McNabb J, Lacy M.K., Quintiliani R., Nightingale C.H. (2001) Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 17(6):497-504
82. Patel GW, Patel N, Lat A., Trombley K, Enbawe S, Manor K et al (2009) Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis 64(2):236-240
83. Patel N, Scheetz MH, Drusano G.L., Lodise T.P. (2010) Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 54(1):460-465
84. Pea F, Viale P, Damiani D., Pavan F, Cristini F, Fanin R et al (2005) Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother 49(8):3550-3553
85. Periti P, Nicoletti P. (1999) Classification of betalactam antibiotics according to their pharmacodynamics. J Chemother 11(5):323-330
86. Peterson LR (2005) Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect 11(Suppl 5):4-16
87. Psathas PA, Kuzmission A, Ikeda K., Yasuo S. (2008) Stability of doripenem in vitro in representative infusion solutions and infusion bags. Clin Ther 30(11):2075-2087
88. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A., Tavakoli H, Gholami K et al (2006) Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 28(2):122-127
89. Rappaz I, Decosterd LA, Bille J, Pilet M., Belaz N, Roulet M. (2000) Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 159(12):919-925
90. Riethmueller J, Junge S, Schroeter T.W., Kuemmerer K., Franke P, Ballmann M et al (2009) Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 37(5):418-423
91. Roberts JA, Boots R, Rickard C.M., Thomas P., Quinn J, Roberts DM et al (2007) Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 59(2):285-291
92. Roberts JA, Kirkpatrick CM, Roberts M.S., Robertson TA, Dalley AJ, Lipman J. (2009a) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64(1):142-150
93. Roberts JA, Webb S, Paterson D., Ho KM, Lipman J. (2009b) A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 37(6):2071-2078
94. Roos JF, Lipman J, Kirkpatrick C.M. (2007) Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 33(5):781-788
95. Roosendaal R, Bakker-Woudenberg IA (1990) Impact of the antibiotic dosage schedule on efficacy in experimental lung infections. Scand J Infect Dis Suppl 74:155-162
96. Roosendaal R, Bakker-Woudenberg IA, van den Berg JC, Michel MF (1985) Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 152(2):373-378
97. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF (1986) Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 30(3): 403-408
98. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel MF (1987) Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro. Pharm Weekbl [Sci] 9(Suppl):S33-S40
99. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel BM (1989) Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 8(10):878-887
100. Safdar N, Maki D.G. (2002) The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 136(11):834-844
101. Schmidt LH, Walley A. (1951) The influence of the dosage regimen on the therapeutic effectiveness of penicillin G in experimental lobar pneumonia. J Pharmacol Exp Ther 103(4):479-488
102. Schmidt LH, Walley A, Larson R.D. (1949) The influence of the dosage regimen on the therapeutic activity of penicillin G. J Pharmacol Exp Ther 96(4):258-268
103. Servais H, Tulkens P.M. (2001) Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 45(9):2643-2647
104. Service AHF (2005) Drug information. American Society of Health-System Pharmacists, Bethesda
105. Sprauten PF, Beringer PM, Louie S.G., Synold TW, Gill M.A. (2003) Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother 47(6): 1991-1994
106. Stiles ML, Mickschl D, Thompson D.F. (1989) Temperature of refrigerated i.v. fluids and admixtures during infusion. Am J Hosp Pharm 46(5):977-979
107. Stiles ML, Allen LV Jr, Fox J.L. (1992) Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs. Am J Hosp Pharm 49(11):2761-2764
108. Stiles ML, Allen LV Jr, Prince S.J. (1995) Stability of various antibiotics kept in an insulated pouch during administration via portable infusion pump. Am J Health Syst Pharm 52(1):70-74
109. Tam VH, Louie A, Lomaestro B.M., Drusano G.L. (2003) Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 23(3):291-295
110. Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein U.M., Locker GJ et al (1999) Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43(4):523-527
111. Tice AD, Rehm SJ, Dalovisio J.R., Bradley JS, Martinelli LP, Graham DR et al (2004) Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 38(12):1651-1672
112. Trissel LA (2006) Handbook on injectable drugs, 14th edn. American Society of Health System Pharmacists, Bethesda
113. Ulldemolins M, Roberts JA, Rello J, Paterson D.L., Lipman J. (2011) The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 50(2): 99-110
114. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA (1999) Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 21(1):63-73
115. van Zanten A.R., Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH (2007) Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 63(1):100-109
116. Vella-Brincat J.W., Begg EJ, Gallagher K, Kirkpatrick C.M., Zhang M., Frampton C et al (2004) Stability of benzylpenicillin during continuous home intravenous therapy. J Antimicrob Chemother 53(4):675-677
117. Viaene E, Chanteux H, Servais H., Mingeot-Leclercq MP, Tulkens P.M. (2002) Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 46(8):2327-2332
118. Vinks AA (2002) The application of population pharmacokinetic modeling to individualized antibiotic therapy. Int J Antimicrob Agents 19(4):313-322
119. Vinks AA, Touw DJ, Heijerman H.G., Danhof M., de Leede GP, Bakker W. (1994) Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit 16(4):341-348
120. Vinks AA, Mouton JW, Touw D.J., Heijerman HG, Danhof M, Bakker W. (1996a) Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother 40(5):1091-1097
121. Vinks AA, Touw DJ, van Rossen RC, Heijerman HG, Bakker W. (1996b) Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT). Pharm World Sci 18(2):74-77
122. Vinks AA, Brimicombe RW, Heijerman H.G., Bakker W. (1997) Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 40(1):125-133
123. Vinks AA, Den Hollander JG, Overbeek SE, Jelliffe RW, Mouton J.W. (2003) Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother 47(2):541-547
124. Vogelman B, Craig W.A. (1986) Kinetics of antimicrobial activity. J Pediatr 108(5 Pt 2):835-840
125. Vogelman B, Gudmundsson S, Leggett J., Turnidge J, Ebert S, Craig W.A. (1988) Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158(4):831-847
126. Walton AL, Howden BP, Grayson L.M., Korman T.M. (2007) Continuous-infusion penicillin home-based therapy for serious infections due to penicillin-susceptible pathogens. Int J Antimicrob Agents 29(5):544-548
127. Waltrip T, Lewis R, Young V., Farmer M, Clayton S, Myers S et al (2002) A pilot study to determine the feasibility of continuous cefazolin infusion. Surg Infect 3(1):5-9
128. Wang D (2009) Experience with extended-infusion meropenem in the management of ventilatorassociated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 33(3):290-291
129. Yost RJ, Cappelletty D.M. (2011) The retrospective cohort of extended-infusion piperacillintazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 31(8):767-775
130. Zeller V, Durand F, Kitzis M.D., Lhotellier L., Ziza JM, Mamoudy P et al (2009) Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations. Antimicrob Agents Chemother 53(3):883-887